BENGALURU — India’s Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said in a statement to stock exchanges.
About 91% of patients treated with the drug tested negative for COVID-19 in standard RT-PCR tests by day seven, compared to nearly 79% who were given the standard of care, the company said citing Phase-III clinical trial data.
The drug, k…
Keep on reading: Approval sought to repurpose Hepatitis C drug for COVID-19 in India